Full-Time

Cardiovascular Sales Manager

Posted on 1/29/2026

Intuitive Surgical

Intuitive Surgical

10,001+ employees

Manufactures robotic surgical systems and services

No salary listed

New York, NY, USA

Remote

Must reside within NYC, Boston, or Philadelphia area or relocate.

Category
Sales & Account Management (2)
,
Requirements
  • 5+ years of medical device sales experience required (preferably within the cardiac space)
  • 1+ years of management experience or management career track required
  • Proven success in previous employment indicating high level of sales achievement
  • Proven ability to develop KOLs and Reference Centers with QTI Data
  • Proven ability to cross partner and work within teams
  • Demonstrate ability to problem solve, manage complexity, and work in an environment of change
  • Excellent planning skills, social skills, and persuasive communication skills
  • Excellent clinical selling skills and ability to build credibility with a highly educated customer base.
  • Track record of sales excellence
  • Ability to travel up to 60%, dependent upon account distribution.
  • Bachelor’s degree required (preferably in science or business)
Responsibilities
  • Expand current Cardiac users across the Eastern/Western US to Total Practice with da Vinci
  • Identify and convert high potential leads in the cardiac space by driving a da Vinci cardiac training pathway resulting in sustainability
  • Build da Vinci Cardiac Reference Centers: demonstrating Clinical, Economic, and New Technology impact
  • Relaunch da Vinci Cardiac pathways to build sustainable da Vinci programs
  • Launch da Vinci ECOSYSTEM to all da Vinci Cardiac Surgeons for programmatic development: Training, Simulation, MACA, HUB, and Case Insights
  • Develop autonomous surgeons, teams, and programs for da Vinci Cardiac
  • Develop and maintain highly technical and clinical expertise with the da Vinci Surgical System platform and procedures to be positioned as adept in providing help for cardiac surgeons and surgical teams starting with specifically in mitral valve procedures and/or IMA harvest: + Educate and train Key Opinion Leaders (KOL’s) on the safe and effective use of the da Vinci Surgical System to improve their robotic surgery techniques and capabilities.
  • Drive and develop care teams through training sessions, helping them know system operations, safety, OR integration, clinical applications and to be effective in pre, intra and postoperative system management.
  • Serve as a dedicated resource to KOL’s and surgical teams, providing guidance and insight on the use of the da Vinci Surgical System through ongoing case assistance.
  • Work with KOL’s and surgical teams to integrate the da Vinci system at existing customer sites and ensure ongoing commitment to the system.
  • Provide basic troubleshooting and service activities on the da Vinci Surgical System as needed.
  • Partner with local ISI sales team and management to execute a clinical plan for KOL’s and surgical teams to ensure they can use the system autonomously within a reasonable time frame
  • Cross partnership with Clinical, Capital, Key Accounts, Marketing, Training and Education to build da Vinci Cardiac
  • Conduct hospital and surgical practice executive presentations
Desired Qualifications
  • Cardiac clinical experience highly preferred.

Intuitive Surgical designs, manufactures, and sells robotic surgical systems and provides related services and accessories for minimally invasive surgery. The core product helps surgeons perform operations with enhanced precision by guiding robotic arms controlled from a console, allowing procedures to be done through small incisions. Instruments and consumables are used with the systems and are supported by service contracts, creating a recurring revenue stream. Compared to competitors, Intuitive has a large installed base and focuses specifically on robotic-assisted surgery, combining devices, disposable instruments, and ongoing services to support hospitals and surgical centers. Its goal is to improve patient outcomes by enabling safer, less invasive procedures while expanding the use and capabilities of robotic surgery for more procedures and providers.

Company Size

10,001+

Company Stage

IPO

Headquarters

Sunnyvale, California

Founded

1995

Simplify Jobs

Simplify's Take

What believers are saying

  • Bariatric surgery market expansion as da Vinci outperforms GLP-1 drugs for sustained weight loss.
  • Ion bronchoscopy system procedures grew 39% YoY with 1,041 installed units capturing lung cancer detection.
  • Less than 5% of eligible surgeries globally performed robotically indicates substantial international adoption runway.

What critics are saying

  • FDA Class II recalls of instruments with fraying cables disrupt 86% of Q1 recurring revenue.
  • FDA safety communication on curved tip staplers halts hospital use, eroding surgeon confidence in reliability.
  • EU MDR recertification deadline December 2028 halts 25% European sales during redesign and testing.

What makes Intuitive Surgical unique

  • 70-80% market share in soft-tissue robotics with 11,395 installed da Vinci systems globally.
  • 85% recurring revenue from instruments, accessories, and service contracts provides predictable cash flow.
  • da Vinci 5 platform expands into cardiac surgery and complex procedures previously requiring open surgery.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Apr 7th, 2026
Intuitive Surgical emerges as dark horse in anti-obesity market as surgery outperforms GLP-1 drugs

Intuitive Surgical could emerge as a dark horse in the anti-obesity market as bariatric surgery proves more effective than GLP-1 drugs for long-term weight loss. A recent study of over 50,000 patients found surgery patients lost an average of 58 pounds after two years, compared to just 12 pounds for those using GLP-1 medications. The study also showed surgery delivers more sustainable results. Gastric bypass patients maintain around 52% of their excess weight loss after 10 years, whilst GLP-1 users often regain all lost weight after stopping treatment. Intuitive's da Vinci surgical system offers minimally invasive bariatric surgery options. The company generated $10.1 billion in revenue last year, up from $8.4 billion, with profit margins around 28%. Despite shares falling over 20% this year, the company's position in surgical innovation makes it a compelling long-term investment.

Yahoo Finance
Mar 29th, 2026
Intuitive Surgical shares drop 19% YTD, but analysts see 15% upside potential

Intuitive Surgical has experienced recent share price weakness, declining 3% in one day with negative returns over the past week, month and three months. The stock currently trades at $452.66, down 10.1% over one month and 19.45% year-to-date, though three-year total shareholder returns remain strong at 77.19%. The medical technology company reports annual revenue of $10.1 billion and net income of $2.9 billion, maintaining a dominant position in minimally invasive surgical technology. According to one valuation analysis, Intuitive Surgical's fair value sits at $532.46, suggesting the stock is undervalued by approximately 15% at current levels. The analysis projects 12% annual revenue growth over the next five years, supported by recurring revenues from spare parts and software licences, with profit margins expected to reach 30% from the current 28.6%.

Yahoo Finance
Mar 28th, 2026
Intuitive Surgical shares up 23% after Jim Cramer's buy recommendation

Intuitive Surgical shares rose 23% following Jim Cramer's recommendation on CNBC's Squawk on the Street in June 2025, where he urged investors to "just go buy ISRG". The medical robotics company experienced a 27% surge in October after reporting third-quarter earnings that beat analyst estimates. Revenue reached $2.51 billion against expectations of $2.40 billion, whilst adjusted earnings per share hit $2.40 versus the predicted $1.98. However, the stock declined 2.7% in January 2026 after Intuitive Surgical released preliminary fourth-quarter results, citing concerns that Medicaid funding cuts and competing products could slow growth of its robotic surgical systems. Despite the recent setback, shares remain up significantly since Cramer's initial endorsement, though they're down 7.8% over the past year.

Yahoo Finance
Mar 28th, 2026
Intuitive Surgical faces tariff headwinds and rising competition despite 19% revenue growth to $2.87B

Intuitive Surgical faces headwinds from tariffs and increased competition in the robotic-assisted surgery market, yet its fundamentals remain strong. The medical device company reported fourth-quarter revenue growth of 19% to $2.87 billion, whilst adjusted earnings per share rose 14.5% to $2.53. Procedures using its da Vinci surgical system increased 17%, with the installed base growing 12% to 11,106 units. However, the stock trades at 47.6 times forward earnings, compared to the healthcare sector average of 17.1. New competition is emerging, with Medtronic's Hugo system recently cleared and Johnson & Johnson expected to launch its own device soon. Despite these challenges, Intuitive Surgical maintains advantages through switching costs and extensive real-world data, whilst the underpenetrated robotic-assisted surgery market offers long-term growth potential.

Yahoo Finance
Mar 24th, 2026
ISRG maintains 37% operating margins in Q4 despite 95 bps tariff drag

Intuitive Surgical maintained a 37% operating margin in Q4 despite tariffs creating a 95 basis point drag, alongside higher facility costs and unfavourable product mix from newer platforms like da Vinci 5 and Ion. The company offset these pressures through product cost reductions, component savings and manufacturing efficiencies. Procedure growth of 18% in Q4 and recurring revenue now comprising 81% of total revenues provided operating leverage. Management's 2026 gross margin guidance of 67-68% suggests continued stability, even as tariff headwinds are expected to increase to roughly 1.2% of revenues. Meanwhile, Boston Scientific expanded adjusted operating margins by 100 basis points to 28% in 2025, though tariffs will offset favourable product mix in 2026. The company expects 50-75 basis points operating margin expansion in 2026 through scale efficiencies and supply-chain optimisation.

INACTIVE